http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 17:13:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Faeth+Therapeutics%2C+Inc.++For%3A+Jun+15/26667228.html si-local-file:///var/storage/secattach/20260618/26667228.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Faeth+Therapeutics%2C+Inc.++For%3A+Jun+15/26667228.html Thu, 18 Jun 2026 17:13:00 -0400 FTH O.49824919 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Faeth+Therapeutics%2C+Inc.++For%3A+Jun+15/26667228.html si-local-file:///var/storage/secattach/20260618/26667228.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Faeth+Therapeutics%2C+Inc.++For%3A+Jun+15/26667228.html Thu, 18 Jun 2026 17:13:00 -0400 FTH O.49824919 http://www.streetinsider.com/Equity+Offerings/faeth+%28FTH%29+files+mixed+shelf/26665873.html <p>faeth (NASDAQ: FTH) has filed mixed shelf of:</p><p>Common Stock</p><p>Preferred Stock</p><p>Debt Securities</p><p>Warrants</p><p><br /> </p> http://www.streetinsider.com/Equity+Offerings/faeth+%28FTH%29+files+mixed+shelf/26665873.html Thu, 18 Jun 2026 16:04:53 -0400 FTH http://www.streetinsider.com/Corporate+News/faeth+%28FTH%29+files+mixed+shelf/26665873.html <p>faeth (NASDAQ: FTH) has filed mixed shelf of:</p><p>Common Stock</p><p>Preferred Stock</p><p>Debt Securities</p><p>Warrants</p><p><br /> </p> http://www.streetinsider.com/Corporate+News/faeth+%28FTH%29+files+mixed+shelf/26665873.html Thu, 18 Jun 2026 16:04:53 -0400 FTH http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Faeth+Therapeutics%2C+Inc.+++++++++++++/26665814.html si-local-file:///var/storage/secattach/20260618/26665814.html http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Faeth+Therapeutics%2C+Inc.+++++++++++++/26665814.html Thu, 18 Jun 2026 16:02:00 -0400 FTH O.49824919 http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Faeth+Therapeutics%2C+Inc.+++++++++++++/26665814.html si-local-file:///var/storage/secattach/20260618/26665814.html http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Faeth+Therapeutics%2C+Inc.+++++++++++++/26665814.html Thu, 18 Jun 2026 16:02:00 -0400 FTH O.49824919 http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html <p>Sensei Biotherapeutics Inc. (NASDAQ: SNSE) announced it has changed its corporate name to Faeth Therapeutics Inc., with its common stock expected to begin trading under the ticker symbol "FTH" on June 16, 2026.</p> <p>The name change follows stockholder approval on June 10, 2026, for the conversion of Series B preferred stock issued in connection with the company's February 2026 acquisition of Faeth Therapeutics and concurrent private placement. The Series B convertible preferred stock will automatically convert into common stock effective June 15, 2026, at 5:00 p.m. ET, subject to beneficial ownership limitations set by each holder.</p> <p>The company received approximately $200 million http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html Mon, 15 Jun 2026 08:10:15 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html <p>Sensei Biotherapeutics Inc. (NASDAQ: SNSE) announced it has changed its corporate name to Faeth Therapeutics Inc., with its common stock expected to begin trading under the ticker symbol "FTH" on June 16, 2026.</p> <p>The name change follows stockholder approval on June 10, 2026, for the conversion of Series B preferred stock issued in connection with the company's February 2026 acquisition of Faeth Therapeutics and concurrent private placement. The Series B convertible preferred stock will automatically convert into common stock effective June 15, 2026, at 5:00 p.m. ET, subject to beneficial ownership limitations set by each holder.</p> <p>The company received approximately $200 million http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html Mon, 15 Jun 2026 08:10:15 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html <p>Sensei Biotherapeutics Inc. (NASDAQ: SNSE) announced it has changed its corporate name to Faeth Therapeutics Inc., with its common stock expected to begin trading under the ticker symbol "FTH" on June 16, 2026.</p> <p>The name change follows stockholder approval on June 10, 2026, for the conversion of Series B preferred stock issued in connection with the company's February 2026 acquisition of Faeth Therapeutics and concurrent private placement. The Series B convertible preferred stock will automatically convert into common stock effective June 15, 2026, at 5:00 p.m. ET, subject to beneficial ownership limitations set by each holder.</p> <p>The company received approximately $200 million http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html Mon, 15 Jun 2026 08:10:15 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html <p>Sensei Biotherapeutics Inc. (NASDAQ: SNSE) announced it has changed its corporate name to Faeth Therapeutics Inc., with its common stock expected to begin trading under the ticker symbol "FTH" on June 16, 2026.</p> <p>The name change follows stockholder approval on June 10, 2026, for the conversion of Series B preferred stock issued in connection with the company's February 2026 acquisition of Faeth Therapeutics and concurrent private placement. The Series B convertible preferred stock will automatically convert into common stock effective June 15, 2026, at 5:00 p.m. ET, subject to beneficial ownership limitations set by each holder.</p> <p>The company received approximately $200 million http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html Mon, 15 Jun 2026 08:10:15 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html <p>Sensei Biotherapeutics Inc. (NASDAQ: SNSE) announced it has changed its corporate name to Faeth Therapeutics Inc., with its common stock expected to begin trading under the ticker symbol "FTH" on June 16, 2026.</p> <p>The name change follows stockholder approval on June 10, 2026, for the conversion of Series B preferred stock issued in connection with the company's February 2026 acquisition of Faeth Therapeutics and concurrent private placement. The Series B convertible preferred stock will automatically convert into common stock effective June 15, 2026, at 5:00 p.m. ET, subject to beneficial ownership limitations set by each holder.</p> <p>The company received approximately $200 million http://www.streetinsider.com/Corporate+News/Sensei+Biotherapeutics+changes+name+to+Faeth+Therapeutics/26644608.html Mon, 15 Jun 2026 08:10:15 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Press+Releases/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html <p class="bwalignc"> <i>— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement —</i> </p><p class="bwalignc"> <i>— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH” on June 16, 2026 —</i> </p><p class="bwalignc"> <i>— Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry —</i> </p><p class="bwalignc"> <i>— PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR http://www.streetinsider.com/Business+Wire/Sensei+Biotherapeutics+Announces+Name+Change+to+Faeth+Therapeutics%2C+Focused+on+Advancing+PIKTOR%2C+an+Oral+Therapy+Targeting+One+of+the+Most+Frequently+Altered+Pathways+in+Cancer/26644605.html Mon, 15 Jun 2026 08:10:00 -0400 A.06822034 FTH O.20026344 O.49824919 SNSE